Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar 20;23(3):176-181.
doi: 10.3779/j.issn.1009-3419.2020.03.07. Epub 2020 Feb 27.

[Research Progress of CDK4/6 Inhibitors in Non-small Cell Lung Cancer]

[Article in Chinese]
Qiong Qin  1 , Yaoyao Ren  1 , Diansheng Zhong  1
Affiliations
Review

[Research Progress of CDK4/6 Inhibitors in Non-small Cell Lung Cancer]

[Article in Chinese]
Qiong Qin et al. Zhongguo Fei Ai Za Zhi. .

Abstract
in English, Chinese

Lung cancer is the leading cause of cancer-related death worldwide. Non-small cell lung cancer (NSCLC) accounts for 80%-85% of lung cancer. Malignant tumors can proliferate indefinitely, and cell cycle regulation is abnormal which is one of the characteristics of malignant tumor. Cyclin D-dependent kinase (CDK) 4/6 inhibitor can prevent tumor cells from entering S phase through G₁ phase and inhibit tumor proliferation. The CDK4/6 inhibitor has achieved good effect in hormone receptor positive breast cancer, and CDK4/6 inhibitor combined with endocrine therapy has become a standard treatment for this kind of patients. Cell cycle regulation is usually abnormal in NSCLC, which incidence is about 22%-45%. CDK4/6 inhibitors have also carried out a series of research and achieved some results, which may become a new treatment in the future. This review focuses on the research progress of CDK4/6 inhibitors in NSCLC, including the mechanism and the approved drugs, clinical research progress in NSCLC, biomarkers for efficacy prediction and current limitations.

【中文题目：CDK4/6抑制剂在非小细胞肺癌治疗中的研究进展】 【中文摘要：肺癌是全球癌症相关死亡的首要原因，非小细胞肺癌（non-small cell lung cancer, NSCLC）占肺癌的80%-85%。恶性肿瘤可以无限增殖，细胞周期失调控是恶性肿瘤特征之一。细胞周期依赖激酶（cyclin D-dependent kinase, CDK）4/6抑制剂能阻滞肿瘤细胞通过G₁期进入S期从而抑制肿瘤增殖，该药物在激素受体阳性乳腺癌中取得了良好的疗效，联合内分泌治疗成为这类患者一线标准治疗。细胞周期失控在NSCLC中比较常见，发生率约为22%-45%，CDK4/6抑制剂也进行了一系列的探索研究，并取得一定的效果，将来有可能成为新的治疗手段。本文重点讨论CDK4/6抑制剂在NSCLC的研究进展，包括作用机制、获批药物、在NSCLC中的临床研究进展、疗效预测生物标记物及局限性等。】 【中文关键词：肺肿瘤；细胞周期蛋白D；CDK4/6抑制剂；生物标记物】.

Keywords: Biomarkers; CDK4/6 inhibitors; Cyclin D; Lung neoplasms.

PubMed Disclaimer

References

    1. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi: 10.3322/caac.21338. - DOI - PubMed
    1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Zhang T, Wan B, Zhao Y, et al. Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment. Transl Lung Cancer Res. 2019;8(3):302–316. doi: 10.21037/tlcr.2019.04.12. - DOI - PMC - PubMed
    1. Thai AA, Solomon BJ. Treatment of ALK-positive nonsmall cell lung cancer: recent advances. Curr Opin Oncol. 2018;30(2):84–91. doi: 10.1097/CCO.0000000000000431. - DOI - PubMed
    1. Almutairi AR, Alkhatib N, Martin J, et al. Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis. Crit Rev Oncol Hematol. 2019;142:16–25. doi: 10.1016/j.critrevonc.2019.07.004. - DOI - PubMed

MeSH terms